MedTrace Logo

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

NCT06552260 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-09-11

No results posted yet for this study

Summary

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.

The name of the study drug involved in this research study is:

-Troriluzole (a tripeptide prodrug of riluzole)

Conditions

Interventions

DRUG

Troriluzole

Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Biohaven Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Ugonma Chukwueke

    lead OTHER

Principal Investigators

  • Ugonma Chukwueke, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2026-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06552260 on ClinicalTrials.gov